Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

What's in Store for Zomedica (ZOM)This Earnings Season?

By Zacks Investment ResearchStock MarketsFeb 11, 2021 09:59PM ET
www.investing.com/analysis/whats-in-store-for-zomedica-zomthis-earnings-season-200560419
What's in Store for Zomedica (ZOM)This Earnings Season?
By Zacks Investment Research   |  Feb 11, 2021 09:59PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

We expect Zomedica ZOM investors to focus on the outlook for the company’s first commercial product, scheduled to be launched on Mar 30, 2021, when it reports fourth-quarter 2020 results.

Shares of the company have soared 1962% in the past year against the industry’s rise of 7.8%.

Zomedica’s earnings performance has been mixed over the trailing four quarters. The company missed expectations in the three of the last four quarters while meeting the same once. The trailing four-quarter average negative earnings surprise is 50.00%.

In the last reported quarter, Zomedica reported a loss of 1 cent per share while the Zacks Consensus Estimate was pegged at breakeven.

Let’s see how things have shaped up prior to this announcement.

Factors to Note

On the fourth-quarter earnings call, investors are likely to focus on launch plans of this veterinary diagnostic company to launch Truforma as a point-of-care diagnosticsfor the detection of adrenal and thyroid disorders in cats and dogs.

Last month, the company signed a distribution agreement with the oldest wholesale veterinary distributor in the United States, Miller Veterinary Supply, to support the launch of Truforma. The company is also focused on developing its internal sales team to support commercialization of Truforma as well.

The company is also developing another point-of-care diagnostic platformdesigned to detect pathogens in companion animals. The company may provide an update on progress with this platform on its fourth-quarter earnings call.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Zomedica this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: Zomedica’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at breakeven.

Zacks Rank: Zomedica currently carries a Zacks Rank #3.

Stocks That Warrant a Look

Here are some stocks from the medical sector that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.

Personalis (NASDAQ:PSNL), Inc. PSNL has an Earnings ESP of +8.48% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Bausch Health Cos Inc. BHC has an Earnings ESP of +7.49% and a Zacks Rank #3.

Atreca (NASDAQ:BCEL), Inc. BCEL has an Earnings ESP of +16.04% and a Zacks Rank #3.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

AccessZacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zomedica Corp. (ZOM): Free Stock Analysis Report

Bausch Health Cos Inc. (BHC): Get Free Report

Personalis, Inc. (PSNL): Free Stock Analysis Report

Atreca, Inc. (BCEL): Free Stock Analysis Report

To read this article on Zacks.com click here.
What's in Store for Zomedica (ZOM)This Earnings Season?
 

Related Articles

Craig Thompson
Bears Firmly In Control By Craig Thompson - Jul 04, 2022 2

Below is a daily chart of the S&P 500 Index. Here are the critical aspects of the chart:The index is in a downtrend defined by a series of lower highs and lower lows. Price...

What's in Store for Zomedica (ZOM)This Earnings Season?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email